XML 44 R33.htm IDEA: XBRL DOCUMENT
v3.20.4

Note 13 - Segment Information (Tables) | 9 Months Ended
--- | ---
Dec. 31, 2020
Notes Tables |
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|  | Three Months Ended December 31, 2020 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 13,077 |  |  | $ | 8,971 |  |  | $ | 8,711 |  |  | $ | 3,413 |  |  | $ | - |  |  | $ | 34,172 |
Gross profit (loss) |  | $ | 9,308 |  |  | $ | 5,368 |  |  | $ | 4,616 |  |  | $ | 1,501 |  |  | $ | (140 | ) |  | $ | 20,653 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (26,380 | )
(Loss) before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (5,727 | )
|  | Three Months Ended December 31, 2019 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 11,619 |  |  | $ | 10,014 |  |  | $ | 5,637 |  |  | $ | 4,156 |  |  | $ | 229 |  |  | $ | 31,655 |
Gross profit (loss) |  | $ | 8,101 |  |  | $ | 6,526 |  |  | $ | (1,294 | ) |  | $ | 1,488 |  |  | $ | (18 | ) |  | $ | 14,803 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (19,880 | )
(Loss) before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (5,077 | )
|  | Nine Months Ended December 31, 2020 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 37,696 |  |  | $ | 24,209 |  |  | $ | 23,791 |  |  | $ | 10,277 |  |  | $ | - |  |  | $ | 95,973 |
Gross profit (loss) |  | $ | 28,098 |  |  | $ | 14,909 |  |  | $ | 15,294 |  |  | $ | 4,053 |  |  | $ | (76 | ) |  | $ | 62,278 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (64,867 | )
(Loss) before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (2,589 | )
|  | Nine Months Ended December 31, 2019 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 35,823 |  |  | $ | 28,518 |  |  | $ | 5,637 |  |  | $ | 11,059 |  |  | $ | 2,442 |  |  | $ | 83,479 |
Gross profit (loss) |  | $ | 25,334 |  |  | $ | 18,164 |  |  | $ | (1,294 | ) |  | $ | 3,994 |  |  | $ | 395 |  |  | $ | 46,593 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (42,471 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 4,122 |
Reconciliation of Assets from Segment to Consolidated [Table Text Block] |
|  | December 31, 2020 |  |  | March 31, 2020 |
Sterilization and Disinfection Control |  | $ | 71,706 |  |  | $ | 73,103 |
Instruments |  |  | 29,967 |  |  |  | 31,025 |
Biopharmaceutical Development |  |  | 205,769 |  |  |  | 182,758 |
Continuous Monitoring |  |  | 28,834 |  |  |  | 29,732 |
Corporate and administrative |  |  | 285,360 |  |  |  | 103,588 |
Total |  | $ | 621,636 |  |  | $ | 420,206 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration